Navigation Links
Other patients bear the real cost of Herceptin

The real cost of Herceptin is borne by other patients whose treatment has to be dropped to balance the books, say doctors in this week’s BMJ.

New guidance from the National Institute for health and Clinical Excellence (NICE) recommends trastuzumab (Herceptin) in early breast cancer, but it provides no extra funding and does not suggest what cuts should be made to release this extra money. This leaves medical staff with difficult decisions to make.

Doctors at the Norfolk and Norwich University Hospital NHS Trust and the University of East Anglia calculated that they will have to find £1.9m each year to make Herceptin available to the patients who may be eligible. This becomes £2.3m if the costs of testing and monitoring patients are added.

But the real cost lies in the services that will be cut to provide this money, they write.

To illustrate this, they audited drug costs in their hospital’s cancer centre and estimated how they could save £1.9m by cutting chemotherapy and palliative care treatments.

The sum of £1.9m would enable us to treat 75 patients with Herceptin, but at four times the cost of the adjuvant treatments, they say. These treatments have been proved to be clinically effective and their estimated cost effectiveness is far greater than that currently expected for Herceptin.

So they could fund Herceptin if they did not treat 355 patients receiving adjuvant treatment (16 of whom would be cured) or 208 patients receiving palliative chemotherapy, and if they found £500,000 from another source.

“These untreated patients will be people we know,?say the authors. “We will be the ones to tell them they are not getting treatment that has been proved to be effective and which costs relatively little, because it is not the treatment of the moment.?

These results are obviously not definitive, but illustrate the fundamental challenge facing the NHS ?the tension between national priority setti ng and local implementation, they add.

This situation highlights our central argument, that as NICE guidance provides no extra funding or any suggestion of which services to cut, medical professionals ultimately have to make these decisions.

Political pressure, patient advocacy and media hyperbole should not be the determinant of who is treated and with what, they argue. In NICE we have an established system, but it is currently creating more problems than solutions.

They believe that NICE should be given responsibility to decide what should be cut to fund newly recommended technologies or the ability to allocate extra funds for implementation, or both.

Source:BMJ-British Medical Journal

Related biology news :

1. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
2. Otherworldly bacteria discovered two miles down
3. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
4. Potential Cure for Lymphoma in HIV patients
5. Ophthalmologists implant five patients with artificial silicon retina microchip
6. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
7. Measuring hormone cuts antibiotic use in half in pneumonia patients
8. Doctors closer to using gene analysis to help trauma patients
9. Research shows smoking adds a decade to reproductive age of IVF patients
10. Columbia study shows widely used artery clearing device does not help patients during heart attack
11. Identification of specific genes predicts which patients will respond to Hepatitis C treatment

Post Your Comments:

(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
Breaking Biology Technology: